These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8208404)

  • 1. Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease.
    Schwarz J; Antonini A; Kraft E; Tatsch K; Vogl T; Kirsch CM; Leenders KL; Oertel WH
    Neurology; 1994 Jun; 44(6):1079-82. PubMed ID: 8208404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
    Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
    Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.
    Schwarz J; Antonini A; Tatsch K; Kirsch CM; Oertel WH; Leenders KL
    Nucl Med Commun; 1994 Oct; 15(10):806-13. PubMed ID: 7838444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease.
    Oertel WH; Tatsch K; Schwarz J; Kraft E; Trenkwalder C; Scherer J; Weinzierl M; Vogl T; Kirsch CM
    Ann Neurol; 1992 Dec; 32(6):743-8. PubMed ID: 1471864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
    Tatsch K; Schwarz J; Oertel WH; Kirsch CM
    Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding.
    Oder W; Brücke T; Kollegger H; Spatt J; Asenbaum S; Deecke L
    J Neural Transm (Vienna); 1996; 103(8-9):1093-103. PubMed ID: 9013397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease.
    Schlaug G; Hefter H; Nebeling B; Engelbrecht V; Weiss P; Stöcklin G; Seitz RJ
    J Neurol; 1994 Oct; 241(10):577-84. PubMed ID: 7836960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers.
    Westermark K; Tedroff J; Thuomas KA; Hartvig P; Långström B; Andersson Y; Hörnfeldt K; Aquilonius SM
    Mov Disord; 1995 Sep; 10(5):596-603. PubMed ID: 8552111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychiatric symptoms as late onset of Wilson's disease: neuroradiological findings, clinical features and treatment.
    Keller R; Torta R; Lagget M; Crasto S; Bergamasco B
    Ital J Neurol Sci; 1999 Feb; 20(1):49-54. PubMed ID: 10933485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of scatter correction on D2 receptor occupancy measurements using 123I-IBZM SPECT: comparison to 11C-Raclopride PET.
    Bullich S; Cot A; Gallego J; Gunn RN; Suárez M; Pavía J; Ros D; Laruelle M; Catafau AM
    Neuroimage; 2010 May; 50(4):1511-8. PubMed ID: 20083205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis.
    Hierholzer J; Cordes M; Schelosky L; Richter W; Keske U; Venz S; Semmler W; Poewe W; Felix R
    J Nucl Med; 1994 Dec; 35(12):1921-7. PubMed ID: 7989970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological and functional imaging in neurological and non-neurological Wilson's patients.
    Hermann W
    Ann N Y Acad Sci; 2014 May; 1315():24-9. PubMed ID: 24495036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms].
    Bettin S; Kämpfer I; Seese A; Schäfer A; Reuter M; Lössner J; Dietrich J; Wagner A; Knapp WH
    Nuklearmedizin; 1997 Aug; 36(5):167-72. PubMed ID: 9380528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
    Ichise M; Toyama H; Fornazzari L; Ballinger JR; Kirsh JC
    J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET.
    Catafau AM; Suarez M; Bullich S; Llop J; Nucci G; Gunn RN; Brittain C; Laruelle M;
    Neuroimage; 2009 Jun; 46(2):447-58. PubMed ID: 19233294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Short interval change of 99mTc-ethyl cysteinate dimer single photon emission computed tomography in Wilson's disease].
    Imai N; Nozaki H; Miyata K; Terayama Y; Ishihara N
    No To Shinkei; 1999 Sep; 51(9):785-9. PubMed ID: 10511956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.